Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Double-blind, Active-controlled, Dose-titrating Efficacy and Safety Study of Firibastat Compared to Ramipril Administered Orally, Twice Daily, Over 12 Weeks to Prevent Left Ventricular Dysfunction After Acute MI

Trial Profile

A Phase 2, Double-blind, Active-controlled, Dose-titrating Efficacy and Safety Study of Firibastat Compared to Ramipril Administered Orally, Twice Daily, Over 12 Weeks to Prevent Left Ventricular Dysfunction After Acute MI

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Dec 2018

At a glance

  • Drugs Firibastat (Primary) ; Ramipril
  • Indications Heart failure; Left ventricular dysfunction
  • Focus Therapeutic Use
  • Acronyms QUORUM
  • Sponsors Quantum Genomics
  • Most Recent Events

    • 19 Oct 2018 Status changed from planning to not yet recruiting.
    • 04 Jul 2018 New trial record
    • 26 Jun 2018 According to a Quantum Genomics media release, Pr Gilles Montalescot (Paris, France) will be the Principal Investigator in this trial will chair an international Steering Committee composed of Pr John H. Alexander (Durham, USA), Pr Leonardo Bolognese (Florence, Italy), Pr Angel-Ramon Cequier (Barcelona, Spain) and Pr Harald Darius (Berlin, Germany).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top